文献速递新发突发、热带与寄生虫病

卢旺达恶性疟原虫kelch13 R561H基因型与延迟寄生虫清除的关联:一项开放标签、单臂、多中心疗效研究

Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.
PubMed 文献 · Lancet Infect Dis · 2021-04-14

该研究于2018年在卢旺达三个中心开展,纳入228例6-59月龄恶性疟单感染发热患儿,采用蒿甲醚-苯芴醇3天疗程并随访28天。

要点

  • 卢旺达出现蒿甲醚-苯芴醇部分耐药证据,但药物仍保持较高治愈率。
  • Pfkelch13 R561H突变与第3天寄生虫清除延迟显著相关。
  • 需持续监测疗效并评估其他抗疟药。

核心结论

  • 研究证实卢旺达出现新发的青蒿素部分耐药证据。
  • 蒿甲醚-苯芴醇仍然有效,但需警惕疗效下降并考虑评估其他抗疟药。

研究设计与样本

  • 开放标签、单臂、多中心治疗疗效研究,2018年在卢旺达Masaka、Rukara和Bugarama三个中心开展。
  • 纳入228例6-59月龄恶性疟原虫单感染且发热的儿童,接受3天蒿甲醚-苯芴醇疗程并随访28天。
  • 主要终点为按WHO方案第28天PCR校正的寄生虫学治愈。

主要发现

  • 治疗前样本中Pfkelch13 R561H突变占28/218(13%),P574L突变占2/218(1%)。
  • Pfkelch13 R561H突变的遗传分析提示其在卢旺达具有共同祖先和本地起源。

关键数值与推荐

  • 部分青蒿素耐药的疑似标准为延迟寄生虫清除,即治疗开始后第3天仍存在寄生虫血症。
  • 治疗前样本中Pfmdr1单倍型240个中217个(90%)为NFD(N86Y、Y184F、D1246Y)或NYD。

临床怎么用

  • 尽管蒿甲醚-苯芴醇仍有效,临床应警惕疗效下降并加强监测。
  • 对延迟寄生虫清除病例可考虑进行Pfkelch13基因型检测以辅助耐药监测。
  • 卢旺达需进一步表征青蒿素部分耐药并评估其他抗疟药。

局限性

  • 研究为单臂设计,未设对照药物组。
  • 仅纳入6-59月龄儿童,结果外推至其他年龄组需谨慎。
  • 随访28天,不足以评估长期疗效和复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Partial artemisinin resistance is suspected if delayed parasite clearance (ie, persistence of parasitaemia on day 3 after treatment initiation) is observed. Validated markers of artemisinin partial resistance in southeast Asia, Plasmodium falciparum kelch13 (Pfkelch13) R561H and P574L, have been reported in Rwanda but no association with parasite clearance has been observed. We aimed to establish the efficacy of artemether-lumefantrine and genetic characterisation of Pfkelch13 alleles and their association with treatment outcomes. METHODS: This open-label, single-arm, multicentre, therapeutic efficacy study was done in 2018 in three Rwandan sites: Masaka, Rukara, and Bugarama. Children aged 6-59 months with P falciparum monoinfection and fever were eligible and treated with a 3-day course of artemether-lumefantrine. Treatment response was monitored for 28 days using weekly microscopy screenings of blood samples for P falciparum. Mutations in Pfkelch13 and P falciparum multidrug resistance-1 (Pfmdr1) genes were characterised in parasites collected from enrolled participants. Analysis of flanking microsatellites surrounding Pfkelch13 was done to define the origins of the R561H mutations. The primary endpoint was PCR-corrected parasitological cure on day 28, as per WHO protocol. FINDINGS: 228 participants were enrolled and 224 (98·2%) reached the study endpoint. PCR-corrected efficacies were 97·0% (95% CI 88-100) in Masaka, 93·8% (85-98) in Rukara, and 97·2% (91-100) in Bugarama. Pfkelch13 R561H mutations were present in 28 (13%) of 218 pre-treatment samples and P574L mutations were present in two (1%) pre-treatment samples. 217 (90%) of the 240 Pfmdr1 haplotypes observed in the pretreatment samples, had either the NFD (N86Y, Y184F, D1246Y) or NYD haplotype. Eight (16%) of 51 participants in Masaka and 12 (15%) of 82 participants in Rukara were microscopically positive 3 days after treatment initiation, which was associated with pre-treatment presence of Pfkelch13 R561H in Masaka (p=0·0005). Genetic analysis of Pfkelch13 R561H mutations suggest their common ancestry and local origin in Rwanda. INTERPRETATION: We confirm evidence of emerging artemisinin partial resistance in Rwanda. Although artemether-lumefantrine remains efficacious, vigilance for decreasing efficacy, further characterisation of artemisinin partial resistance, and evaluation of additional antimalarials in Rwanda should be considered. FUNDING: The US President's Malaria Initiative. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021. PMID: 33864801. doi:10.1016/S1473-3099(21)00142-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。